Cambridge Healthtech Institute’s Inaugural

Modality Selection for Next-Gen Biotherapeutics

September 17-18, 2020

 

As the industry gains more experiences with biotherapeutics, the concept of an agnostic approach to modality selection is becoming more common in early discovery, with the premise of automatically moving a target into a given product format and giving way to a comprehensive examination of alternatives. New screening assays and technologies and a trend toward pushing functional studies earlier in the process are blending with an increasing range of options for achieving desired specificity, MOA and safety. DOT's Modality Selection conference considers the state of the science for complex antibody formats, expanding applications of cell and gene therapies and clinical perspectives on the use of biotherapeutics in patients. The program also examines options for unique circumstances including receptor agonism, alternate routes of administration, and delivery to the brain and CNS.

 

Coverage will include, but is not limited to:

The State of the Science for Therapeutic Antibody Modalities

  • Bi- and multi-specific antibodies
  • Antibody-drug conjugates
  • Antibody-like molecules; modified proteins
  • Naked antibodies; are novel constructs necessary in all cases?

Cell and Gene Therapies

  • CAR Ts
  • Cellular therapies
  • Gene therapies
  • Vectorized antibody discovery and delivery

Modality Selection for Unique Requirements

  • Unique routes of administration; localized delivery
  • Agonistic effects
  • Therapeutics for multiple targets (multispecifics, mixtures/co-formulations); controlling polyspecificity
  • Trafficking in the brain

Clinical Perspectives: What Do Physicians Want?

  • Pharma medical perspective; selecting modalities for a specific biology or disease
  • Physician perspective: cancer immunotherapies
  • Physician perspective: the role of biologics in autoimmunity and inflammation
  • Physician perspective: biologic modalities and next generation discovery approaches for large-scale infectious diseases

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is February 26, 2020.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199
Email: ksimmons@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com